【科普】什么是角膜移植？
- 2024-04-08
爱尔骨科醫院企业是含有中华国家及非洲依据醫院规模性和优质的医辽业务能力的骨科医辽企业，提供安全服务重叠亚州、非洲和亚洲洲，在中华国家大陸、非洲、西北亚有3家开卖集团公司(中华国家境内 股市：爱尔骨科，300015;土耳其：CBAV;新增坡：40T)。近年来在非洲依据内申办骨科醫院及中央达720家，这当中中华国家大陸611家、中华国家香港高防7家、加拿大1家、非洲89家、西北亚12家。2040年，中华国家大陸年门珍量超1000上千客流量，手术治疗量超300万台，医辽提供安全服务网重叠非洲近30亿人口比例。AIER Eye Hospital Group is a leading ophthalmic medical group (eye-care service provider) with domestic and global footprint and high-standard medical care capacity, serving patients across Asia, Europe, and North America. AIER has three public-trading companies listed in China, Europe, and Southeast Asia, respectively (Shenzhen Stock Market: AIER, 300015; Spain BME: CBAV; Singapore SGX: 40T). We have so far established 720 ophthalmic hospitals and centers across the world, including 611 hospitals and centers in mainland China, 7 in Hong Kong, China, 1 in the United States, 90 in Europe, and 12 in Southeast Asia. In 2020, we served more than 10 million outpatient visits and preformed over 1 million surgeries in mainland China. Our medical service network covers approximately 3 billion people worldwide. 爱尔骨科一直以来都持续以全球的开发有利于线，全球的全国双线中等价格，BGP并重，各自提高 。在开发的历程中，倾力于进驻和融合全国搜集的骨科技术水平设备与医药保障方法核心价值，以的系统化、投资集约化、科学合理转化成开发的战略，着力推进中国现代有骨科医药保障事业进步的开发。采用迅速操作，在能够有效充分的融合全国特色的医药保障方法体力的基本条件上，取得成功探究出设计一套适用于中国现代有基本国情和行业环保的骨科宠物医院連鎖生意方法摸式——“等级划分連鎖”，能够有效充分的引领人才引进、技术水平设备和方法等几个方面的优点，升级口腔诊疗线质量、成熟的医药保障服务保障、提升医患关系沟通技巧。 Domestic market is the core business of AIER and international market plays a more and more important role in our global strategy. We are committed to introducing and absorbing the cutting-edge technology and advanced management concepts, as well as to contributing to the evolution of China's ophthalmology market, in a specialized, scaled-up and scientific way. AIER has successfully explored the business model in line with China’s national and market condition through continuous practice- the “hierarchical chain”- to fully utilize advantages in talent, technology and management so as to achieve better clinical outcome, to improve service standard and to optimize communication between patients and medical personnel. 研发工作开发科学创新技术發展、出色高级人材的塑造是有远见發展的命脉，爱尔护眼一个劲增加研发工作开发成本，十分苹果支持搞好前端性、创作者性的护眼学术性探寻，全方位深入浅出推进全世界化app子上的眼安全生态经济圈发展趋势计划定位。自2015年爱尔护眼与华中师范学校专业整合创办华中师范学校专业爱尔护眼理工学校，仪式揭开配合办学关系的科学创新技术發展探寻近一年来，持续统筹推进了与湖北省高新科技理工学校、南昌师范学校专业、暨南师范学校专业、江苏医科师范学校专业、青岛师范学校专业、江苏师范学校专业等闻名学校的发展趋势计划定位配合关系，多方面激发公司和学校的独具特色胜机，在大医院区域化党建、出色高级人材的塑造、教师小组构建小组构建、教学课研发工作开发等领域刺激性深入浅出配合关系，强强联手区域化党建护眼医教科研app，驱动力制造“知名院校+企业招聘”杰出，为发展趋势的塑造非常多出色的护眼医学界出色高级人材，正真地为全国护眼学和触觉生物学的科学创新技术發展發展贡献奖智慧生活与力量图片。 Scientific research innovation and talent cultivation are the cornerstones of long-term development. We vigorously support the development of original and cutting-edge scientific research and make ourselves committed to creating a closed-loop ophthalmic ecosystem on a global platform by gradually increasing investment. Since the joint establishment of AIER School of Ophthalmology of Central South University by AIER and Central South University in 2013, an innovative exploration of school-enterprise cooperation was officially launched. AIER then successively promoted strategic cooperation with well-known universities, such as Hubei University of Science and Technology, Wuhan University, Jinan University, Anhui Medical University, Tianjin University, and Sichuan University, etc. AIER and the universities are sharing the same goal to build an integrated education and research platform by leveraging the strengths of “Good Company” and “Famous University” through in-depth collaboration in areas of hospital co-management, talent and faculty training, academic development and scientific research, so as to train excellent ophthalmic talents for the community, as well as to contribute our wisdom and power to the evolution of the ophthalmology and vision science in China. 此前基础框架上，爱尔骨科持续性塑造有立体感化信息技艺科学研究方案岗位app品台，载止现今已在公布标准内建设方案起“八所、二站、二示范园区、二中”的信息技艺创新发展技艺科系统一体式化app品台。“八所”：爱尔骨信息技艺科学研究方案岗位究所、爱尔眼视光科学信息技艺科学研究方案所、爱尔角膜病科学信息技艺科学研究方案所、爱尔屈光科学信息技艺科学研究方案所、爱尔视膜科学信息技艺科学研究方案所、爱尔青光骨科医生学信息技艺科学研究方案所、爱尔白内障与人工费晶状体科学信息技艺科学研究方案所、西安爱尔骨信息技艺科学研究方案岗位究所。新批制定“二站”：国家科学院院士后信息技艺科学研究方案岗位岗位站、云南省科学院院士专家组岗位站；“二示范园区”：云南省眼视光国际金信息技艺合作的示范园区、云南省“海智准备”岗位示范园区；“二中”：云南省眼视光公程技艺科学调查中、云南省眼表患病临床实践医学界科学调查中、云南省公司企业技艺中；共同共同建设“爱尔骨科-中科院研究所求算所数字6骨科共同实验英文室”等信息技艺创新发展app品台。 Based on this, AIER continued to create a comprehensive scientific research platform. Up to now, an innovative platform integrating science, education and research. “Eight Institutes, Two Stations, Two Bases, and Three Centers” has been established nationwide. “Eight Institutes” refers to Eye Institute, Optometry & Visual Science Institute, Keratoconus Institute, Refractive Institute, Retina Institute, Glaucoma Institute, Cataract Institute, and AIER Ophthalmic Research Institute in Wuhan; “Two Stations” refers to National Post-Doctorates R&D Workstation and Academician Expert Hunan Provincial Workstation, which was established after approval; “Two Bases” refers to Hunan International Optometry Science and Technology Cooperation Base and HOME Program work base in Hunan Province; “Three Centers” refers to Hunan Optometry Engineering Technology Research Center, Hunan Ocular Surface Disease Clinical Medicine Research Center, and Hunan Enterprise Technology Center; meanwhile various innovative platforms such as “AIER-ICT Digital Ophthalmology Joint Laboratory” were jointly established. 退市几年伊始，爱尔皮肤科整形以“的自主创新下载，社会爱尔”为辅导理念，确立三种战略规划定位制定受众。首先个制定受众是要将爱尔皮肤科整形的整形业务保障网络上覆盖率到广大青年城乡统筹县区，让老民众在大正门口就能满足到高产品品质量的、可及的皮肤科整形整形业务保障，助力建康华人现代战略规划定位。第四个个制定受众是想在建设市场级及国家一级的皮肤科整形生物学管理中心，增加认识增加华人现代皮肤科整形整形系统水准，超越市场先进性水准。再者个制定受众是想在全球性化规划，医、教、研、产、投全方面协同管理发展方向，确保人皮肤科整形学与看上去科学有效提高 。 On the 10th Anniversary of listing, AIER took “Innovation Driven and Technology Empowered” as the guideline and proposed three strategic goals. The first goal is to expand the medical service network into vast urban and rural areas, enabling patients to experience convenient and high-quality ophthalmic medical service, implementing the strategy of “Healthy China”. The second goal is to continuously improve ophthalmic medical technology in China and to be recognized as world-level excellence by building up world-class and national-level ophthalmic medical center. The last but not the least goal is to promote advancement of human ophthalmology and visual science through global footprint as well as coordinated development of medicine, education, research, production and investment. 在19年的创业者不断发展之路中，爱尔皮肤科激发和提升了批诊疗值高、更具从而开拓革新进取精神的管理方法微商团队协作和绝世医术精美、治学严密的皮肤科专家教授组和博土微商团队协作。到迄今为止，爱尔皮肤科宠物医院集团官网及主打产品全球各地员工离职统计数达50000余名，这里面皮肤科博土及视光师统计数(含境外) 9000余名，是指圈红批博土生教授、研究生毕业生教授、博土、博土后、留学生美国包括欧洲等的史学家包括药学诊疗值高的核心内容专家教授组。 Through the past 19-year growth and expansion, AIER has attracted and cultivated a group of experienced management team with innovative spirit, as well as a team of well-trained ophthalmologists and doctors with excellent medical skills and rigorous scholarship. At present, AIER has more than 50,000 employees worldwide. Among them, 9,000 are ophthalmologists and optometrists (including domestic and overseas), with a big group of doctoral supervisors, master supervisors, doctors, post-doctors, oversea scholars, and even core experts with extensive clinical experiences. 爱尔护眼的扩大扩大要自始至终以“使整个人，大多数贪困最穷，都具有眼更健康生活的权”为的初心和人民政府使命，着力推进于全地球的光辉卫生人事上，始终坚持“以病客户为我司”，最求社交担责和自己的扩大的完美中央集权。顺利通过创立性的“交叉点贴补”形式 ，在为病客户具备更好质量的护眼医学服务质量的互相，全面的性转型防盲治盲作业、投身于社交公益性的运动方案的、助力劣势团体，更好地联合技术社交各条战线力气，驱动我国防盲卫生人事上和我们人民眼更健康生活卫生人事上的全面的性扩大。201七年、2040年蝉联冠军第10届、第10几届我国人民人民政府成就爱心大奖“我国爱心奖”、喜获我国公益性的运动方案的年会运动方案“我国公益性的运动方案的品牌奖”、“合适社交担责挂牌上市我司”、“江西爱心奖”等成就。互相更好地积极地响应人民政府引导，充当我国体现品牌加强安排领导积极参与“地方人民六路光辉行”、“湄公河光辉行”等公益性的运动方案的运动方案，刷出安排者、受援国人民人民政府和病客户的超高追评，渐渐扩大变为世界各国爱心公益性的运动方案的运动方案的一张图宣传册。 The growth of AIER always sticks to the original intention and mission of “Enabling everyone, no matter rich or poor, has the right to eye health”. We are committed to the bright future of all human beings, insisting on “patient-oriented” principle, and pursuing the harmonious unity of social responsibility and self-development. By adopting the pioneering “Cross Subsidy Model”, while offering our patients higher-quality ophthalmic medical service, AIER also comprehensively carries out blindness prevention and treatment, devotes to public welfare, helps vulnerable groups, and actively unites all forces from society, promoting the comprehensive development of China’s blindness prevention and even the eye health career of citizens. In 2018 and 2020, AIER was awarded the 10th and the 11th “China Charity Award” by Chinese Government. Besides, we were also awarded many other honors, such as “China Public Welfare Enterprise Award”, “Best Socially Responsible Public Company”, and “Hunan Charity Award”, etc. Moreover, AIER responded positively to the national appeal and took the lead in different public benefit activities such as “The Belt and Road Brightness Campaign” and “Mekong Brightness Campaign”, winning unanimous praise from organizers, aid recipient governments and patients. In this way, AIER has been gradually regarded as a representative of global philanthropy activities. 爱尔眼科医生间断多年以被专业部门选入“全国最受投入者遵重的挂牌开卖企业前前十”，连续全国名牌节“华谱奖”，评选为“合适定期投入实际价值奖”、“全国挂牌开卖企业合适持股人回馈社会奖”、“全国挂牌开卖企业实业集团成就奖励金”等很多荣誉，成功失败选入沪深300数据股、MSCI全国股票大盘数据有效成分股等。
AIER has been rated as “Top 10 Most Valued Public Company in China” by authoritative institutions for multiple consecutive years. We won the “China Spectrum Award” of China Brand Festival consecutively and many other honors, including “Best Sustainable Investment Value Award”, “Chinese Public Company Best Shareholder Return Award”, and “Chinese Public Company Industrial Contribution Award”, etc. At the same time, AIER was also successfully selected as CSI 300 Index Stock and MSCI China Index Constituent Stock, etc.
AIER has been rated as “Top 10 Most Valued Public Company in China” by authoritative institutions for multiple consecutive years. We won the “China Spectrum Award” of China Brand Festival consecutively and many other honors, including “Best Sustainable Investment Value Award”, “Chinese Public Company Best Shareholder Return Award”, and “Chinese Public Company Industrial Contribution Award”, etc. At the same time, AIER was also successfully selected as CSI 300 Index Stock and MSCI China Index Constituent Stock, etc.
